Spots Global Cancer Trial Database for CT-Guided Adaptive Radiation Therapy Combine With Anti-PD-1 Antibody Adjuvant Immunotherapy for Thoracic Cancer Patients

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: CT-Guided Adaptive Radiation Therapy Combine With Anti-PD-1 Antibody Adjuvant Immunotherapy for Thoracic Cancer Patients

Official Title: A Safety and Efficacy Study of CT-Guided Adaptive Radiation Therapy With Anti-PD-1 Antibody Adjuvant Immunotherapy in Patients With Thoracic Cancer (CARTAI)

Study ID: NCT03732430

Conditions

Thoracic Malignancies

Interventions

IBI308

Study Description

Brief Summary: This phase II study is to evaluate the safety and efficacy of CT-based adaptive radiation therapy followed by adjuvant anti-PD-1 antibody immunotherapy in treating patients with different types and stages of thoracic malignancies. (CARTAI)

Detailed Description: PRIMARY OBJECTIVES: I. To evaluate the safety and toxicity of anti-programmed cell death 1 (PD-1) inhibition consolidation therapy after radiation therapy for multiple thoracic malignancies. SECONDARY OBJECTIVES: I. To assess the efficacy of adjuvant anti-PD-1 antibody immunotherapy after radiotherapy. II. To understand the dynamics and interactions of IDO with others immune pathway biomarkers. III. To evaluate whether IDO immune status could predict the treatment outcomes of radiation and immune combined therapy.